A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in

See also
Status	Clinical Trial	Phase
Completed	`NCT02916979` - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG	Phase 1
Not yet recruiting	`NCT06345495` - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly	Phase 2
Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
Completed	`NCT02784496` - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis	Phase 2
Completed	`NCT00069680` - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting	`NCT04097821` - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting	`NCT06024915` - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets	Phase 1
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Completed	`NCT02910258` - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00997386` - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States	Phase 2
Completed	`NCT00666549` - Research Tissue Bank
Terminated	`NCT00393380` - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor	Phase 2
Terminated	`NCT00522990` - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias	Phase 1/Phase 2
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Active, not recruiting	`NCT03952039` - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Phase 3
Not yet recruiting	`NCT04709458` - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis	Phase 1
Recruiting	`NCT04988815` - Ropeginterferon Alfa 2b for Early Myelofibrosis	Phase 2

NCT number	NCT06245941
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Hong yan Tong, Doctor
Phone	13958122357
Email	tonghongyan@zju.edu.cn
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	February 2024
Completion date	May 2027

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms